This study is completed in Japan. It is testing JNS001 for ADHD.
ADHD, Attention-Deficit / Hyperactivity DisorderDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether JNS001 may be useful for adults experiencing ADHD.
What would participation involve?
Participants may receive JNS001, attend study visits with the research team. The registry lists locations in Japan.
Who is it mainly for?
This study appears to be mainly for adults with ADHD.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateMay 2011
Recruitment status
Completed
Enrollment listed in the registry
253
Sponsor
Janssen Pharmaceutical K.K.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan
Age range
From 18 Years to 65 Years
Official registry ID
NCT01357993
Official title
An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Japan · 29 sites
Chiba
Chiba
Site status: Not listed — confirm with the team
Chigasaki
Chigasaki
Site status: Not listed — confirm with the team
Chiyoda City
Chiyoda City
Site status: Not listed — confirm with the team
Fuchū
Fuchū
Site status: Not listed — confirm with the team
Fukuoka
Fukuoka
Site status: Not listed — confirm with the team
Fukushima
Fukushima
Site status: Not listed — confirm with the team
Hamamatsu
Hamamatsu
Site status: Not listed — confirm with the team
Higashiosaka
Higashiosaka
Site status: Not listed — confirm with the team
Ichikawa
Ichikawa
Site status: Not listed — confirm with the team
Iruma
Iruma
Site status: Not listed — confirm with the team
Isehara
Isehara
Site status: Not listed — confirm with the team
Kashihara
Kashihara
Site status: Not listed — confirm with the team
Kishiwada
Kishiwada
Site status: Not listed — confirm with the team
Kobe
Kobe
Site status: Not listed — confirm with the team
Kumamoto
Kumamoto
Site status: Not listed — confirm with the team
Kurume
Kurume
Site status: Not listed — confirm with the team
Matsuyama
Matsuyama
Site status: Not listed — confirm with the team
Nagasaki
Nagasaki
Site status: Not listed — confirm with the team
Nagoya
Nagoya
Site status: Not listed — confirm with the team
Nara
Nara
Site status: Not listed — confirm with the team
Neyagawa
Neyagawa
Site status: Not listed — confirm with the team
Osaka
Osaka
Site status: Not listed — confirm with the team
Saitama
Saitama
Site status: Not listed — confirm with the team
Sakai
Sakai
Site status: Not listed — confirm with the team
Sapporo
Sapporo
Site status: Not listed — confirm with the team
Shibuya City
Shibuya City
Site status: Not listed — confirm with the team
Takatsuki
Takatsuki
Site status: Not listed — confirm with the team
Tokyo
Tokyo
Site status: Not listed — confirm with the team
Yokohama
Yokohama
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01357993. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving JNS001. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with adhd; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen Pharmaceutical K.K., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
